Jeffrey W. Moses, MD

Sirolimus-eluting and paclitaxel-eluting stents decrease neointimal hyperplasia leading to a reduction, but not elimination, of in-stent restenosis.1–4 Because sirolimus and paclitaxel decrease neointimal hyperplasia, restenosis is dependent...

Sirolimus-eluting and...

08/01/2008

Journal of Invasive Cardiology

Original Contribution

Robotic-Enhanced PCI Compared to the Traditional Manual Approach

07/08/2014

Kate E. Dalton , MS;

Nathaniel R. Smilowitz , MD, MS;

Lauren T. Privitera , MPH;

Diane Canone-Weber , MPH;

Jeffrey W. Moses , MD;

Giora Weisz , MD;

Varinder Singh , MD;

Martin B. Leon , MD;

Fernando A. Sosa , BA;

Benjamin Lerman , BA;

Yasir Qureshi , MD;

Remote-controlled robotic-enhanced percutaneous coronary intervention (PCI) was developed to improve procedural outcomes, reduce operator radiation exposure, and improve ergonomics. Critics questioned whether protection of the operator might...

Remote-controlled...

07/08/2014

Journal of Invasive Cardiology

Original Contribution

Temporal Trends in Chronic Total Occlusion Percutaneous Coronary Interventions: Insights From the PROGRESS-CTO Registry

03/20/2020

Emad Hakemi , MD;

Santiago Garcia , MD;

Emmanouil S. Brilakis , MD, PhD, FACC, FAHA, FESC, FSCAI;

M. Nicholas Burke , MD;

Subhash Banerjee , MD, FSCAI;

Khaldoon Alaswad , MD;

Fotios Gkargkoulas , MD;

Shuaib M. Abdullah , MD;

Iosif Xenogiannis , MD;

Dimitrios Karmpaliotis , MD, PhD;

Allison Hall , MD;

Farouc A. Jaffer , MD, PhD;

Robert W. Yeh , MD, MBA, MSc;

Nicholas J. Lembo , MD;

Anthony H. Doing , MD;

Jeffrey W. Moses , MD;

Catalin Toma , MD;

Ziad A. Ali , MD, DPhil;

James W. Choi , MD;

Manish A. Parikh , MD;

Oleg Krestyaninov , MD;

Aris Karatasakis , MD;

Ehtisham Mahmud , MD;

Dmitrii Khelimskii , MD;

Barbara Anna Danek , MD;

Mitul P. Patel , MD;

Philip Dattilo , MD;

Bavana V. Rangan , BDS, MPH, MD;

Evangelia Vemmou , MD;

Ajay J. Kirtane , MD, SM;

Juan Russo , MD;

Ilias Nikolakopoulos , MD;

Barry F. Uretsky , MD;

Abstract: Background. Chronic total occlusion (CTO) percutaneous coronary intervention (PCI) has significantly evolved in recent years. Methods. We compared the clinical, angiographic, and technical characteristics, as well as procedural...

Abstract: Background. Chronic...

03/20/2020

Journal of Invasive Cardiology

Systemic Anaphylactoid Reactions to Iodinated Contrast Media During Cardiac Catheterization Procedures:Guidelines for preventi

06/19/2008

Jerome E. Goss , MD;

Charles E. Chambers , MD;

Frederick A. Heupler , MD;

Jeffrey W. Moses , MD;

Arfan J. Al-Hani , MD;

William T. Armstrong , MD;

Airlie A.C. Cameron , MD;

Wayne E. Dear , MD;

Stephen Balter , PhD;

Manuel de la Llata , MD;

Larry S. Dean , MD, FACC, FAHA, FSCAI;

John P. Dervan , MD;

James C. Dillion , MD;

Lowell I. Gerber , MD;

Kenneth R. Jutzy , MD;

Francis Y.K. Lau , MD;

William J. Phillips , MD;

Sheldon S. Sbar , MD;

William C. Sheldon , MD;

Neal S. Kleiman , MD;

This report represents the first guidelines for prevention, diagnosis, and treatment of anaphylactoid reactions to contrast media occurring specifically during cardiac catheterization. The incidence of contrast media complications in the...

This report represents the first...

06/19/2008

Cath Lab Digest

Clinical Editor's Corner

“Let the Patient Eat.” Isn’t It Time to Change the NPO Rule for the Cath Lab?

01/31/2016

Arnold H. Seto , MD, MPA, CCDS, FACC, FSCAI;

Jeffrey W. Moses , MD;

Samuel M. Butman , MD;

Allen Jeremias , MD, MSc;

Kirk N. Garrett ;

Pinak Bipin Shah ;

John Bittl , MD;

James C. Blankenship , MD;

Sunil V. Rao , MD, FACC, FSCAI;

Morton J. Kern , MD, MSCAI, FACC, FAHA;

What is the rationale for continuing the NPO order

What is the rationale for...

01/31/2016

Cath Lab Digest

Original Contribution

Initial Clinical Experience Using an Ostial Stent Positioning System (Ostial Pro‚Ñ¢) for the Accurate Placement of Stents in the

02/10/2009

Jeffrey W. Moses , MD;

From Borgess Heart Institute, Kalamazoo, Michigan; §Heart & Vascular Adventist Midwest Health, Lagrange, Illinois; †Baptist Hospital, Knoxville, Tennessee; √Weill Cornell Medical College, New York Hospital, New York, New York; *Columbia...

From Borgess Heart Institute,...

02/10/2009

Journal of Invasive Cardiology

Original Contribution

Mechanical Circulatory Support in Chronic Total Occlusion Percutaneous Coronary Intervention: Insights From a Multicenter U.S. Registry

02/25/2018

Khaldoon Alaswad , MD;

Dimitrios Karmpaliotis , MD, PhD;

Farouc A. Jaffer , MD, PhD;

Robert W. Yeh , MD, MBA, MSc;

Michael R. Wyman , MD;

Emmanouil S. Brilakis , MD, PhD, FACC, FAHA, FESC, FSCAI;

Nicholas J. Lembo , MD;

Jeffrey W. Moses , MD;

Subhash Banerjee , MD, FSCAI;

Anthony H. Doing , MD;

Ziad A. Ali , MD, DPhil;

David E. Kandzari , MD;

Craig A. Thompson , MD, MMSc;

Manish A. Parikh , MD;

William W. O'Neill , MD;

Catalin Toma , MD;

Aris Karatasakis , MD;

James W. Choi , MD;

Barbara Anna Danek , MD;

Mir Babar Basir , MD, DO;

Judit Karacsonyi , MD, PhD;

Mohammad Alqarqaz , MD;

Bavana V. Rangan , BDS, MPH, MD;

Ajay J. Kirtane , MD, SM;

Ehtisham Mahmud , MD;

William L. Lombardi , MD;

Mitul P. Patel , MD;

Santiago Garcia , MD;

We examined the characteristics and outcomes of 1598 CTO-PCIs. Despite more complex clinical and angiographic characteristics, we found that elective use of mechanical circulatory support (MCS) in high-risk patients was associated with...

We examined the characteristics...

02/25/2018

Journal of Invasive Cardiology

A 3D CT Vessel Roadmap Over Live Fluoroscopy for Chronic Total Occlusion

06/19/2008

Jeffrey W. Moses , MD;

What is the first step in using this technology? It has two aspects. First of all, CTA is the foundation. We are building on an emerging treatment paradigm for total occlusions that uses cardiac CTA as a primary planning tool. The final step,...

What is the first step in using...

06/19/2008

Cath Lab Digest

Clinical Editor's Corner

Whatever Happened to the Routine Use of Protamine?

08/04/2021

Mauricio G. Cohen , MD, FACC;

Bonnie H. Weiner , MD, MBA, FSCAI, FACC;

Steven R. Bailey , MD;

Stephen R. Ramee , MD;

Nils P. Johnson , MD, MS;

Farouc A. Jaffer , MD, PhD;

Samuel M. Butman , MD;

Jeffrey Marshall ;

Kreton Mavromatis , MD;

Chet Rihal ;

Gurpreet S. Sandhu , MD, PhD;

Kirk N. Garrett ;

Morton J. Kern , MD, MSCAI, FACC, FAHA;

Pranav M. Patel ;

Jeffrey W. Moses , MD;

Dean J. Kereiakes , MD, FACC, FSCAI;

Steven L. Goldberg , MD;

Neal S. Kleiman , MD;

Early in the field of cardiac catheterization, heparin anticoagulation was required for almost every procedure in order to prevent thrombosis on the catheter, as the initial catheter materials, like Dacron, were highly thrombogenic. Often the...

Early in the field of cardiac...

08/04/2021

Cath Lab Digest

Original Contribution

The Relative Effects of Abciximab and Tirofiban on Platelet Inhibition and C-Reactive Protein during Coronary Intervention

01/07/2010

Edward M. Kreps , MD;

Martin B. Leon , MD;

Alexandra J. Lansky , MD;

George D. Dangas , MD, PhD;

Adam J. Saltzman , MD;

Roxana Mehran , MD;

W. Craig Hooper , PhD;

Jeffrey W. Moses , MD;

Giora Weisz , MD;

Michael B. Collins , MD;

Gregg W. Stone , MD, FACC, FSCAI;

ABSTRACT: Background. We sought to compare the efficacy of tirofiban and abciximab on platelet inhibition as well as their effects of platelet inhibition on C-reactive protein levels during percutaneous coronary intervention (PCI). Methods....

ABSTRACT: Background. We sought...

01/07/2010

Journal of Invasive Cardiology